April 26, 2018 9:26 PM ET

Pharmaceuticals

Company Overview of Alvogen, Inc.

Company Overview

Alvogen, Inc. manufactures generic and brand medicines, biosimilars, and over the counter (OTC) medicines. The company focuses on niche generics, pathces, controlled releases, and narcotics in various forms, including solid oral dosage forms, soft gelatin capsules, modified release tablets, transdermals, creams, ointments, and injectables. Its portfolio includes a range of molecules for the treatment of conditions in the fields of oncology, cardiology, respiratory, neurology, and gastroenterology. The company also sells and markets a portfolio of OTC medicines and medical devices. In addition, it promotes and distributes a range of biosimilar products in various therapeutic areas; and offers...

10 Bloomfield Avenue

Pine Brook, NJ 07058

United States

Founded in 2008

Phone:

973-796-3400

Fax:

973-215-2280

Key Executives for Alvogen, Inc.

Executive Chairman and Chief Executive Officer
Chief Financial Officer
Member of Executive Board and Chief Executive Officer of Alvogen America
Age: 47
President of Alvogen America
Executive VP, Member of Executive Board & Director
Age: 52
Compensation as of Fiscal Year 2017.

Alvogen, Inc. Key Developments

Noven Pharmaceuticals, Inc. Files Patent Infringement Lawsuit Against Alvogen, Inc. and Alvogen Pine Brook, LLC

Noven Pharmaceuticals, Inc. announced that it has filed a lawsuit in the U.S. District Court of Delaware against Alvogen, Inc. and Alvogen Pine Brook, LLC. for patent infringement. Alvogen is seeking approval to market and sell a generic version of Minivelle® (estradiol transdermal system) prior to the expiration of two of Noven’s Orange Book listed patents (U.S. Patent Nos. 9724310 and 9730900). The lawsuit reflects Noven’s commitment to vigorously enforce its intellectual property rights against infringement.

Alvogen, Inc. Wins $6.02 Million Federal Contract

Alvogen Inc. won a federal contract valued at up to $6,017,237.19 from the Defense Logistics Agency for pharmaceutical products.

Alvogen Seeks Alternatives For Generics Business

Alvogen, Inc. is considering multiple strategic alternatives for their generics businesses. Alvogen has been talking to advisers about strategic options for their generics businesses, ranging from acquisitions to increase scale to an outright sale of the units, people familiar with the matter said this week. The persons declined to speak for attribution because the discussions are private.

Similar Private Companies By Industry

Company Name Region
Praetego, Inc. United States
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
August 15, 2017
OOO Bittner Pharma
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Alvogen, Inc., please visit www.alvogen.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.